MUMBAI, India, June 22 -- Intellectual Property India has published a patent application (202621019987 A) filed by Dr. Jalari Ramu; Dr. Krupavaram. B; Dr. K. Vinod Kumar; Badri. Sirisha; Ramireddy Harshith Reddy; Dr. Kasetti Ashok; Dr. Manju Navaneetham; Dr. Kannan Kilavan Packiam; Dr. Sattenapalli Lakshmi Savithri; and Vinjavarapu Lakshmi. Anusha on February 20, 2026, for Nanoparticle-Based Controlled Drug Delivery System For Enhanced Brain Targeting In Neurodegenerative Disorders.
Inventors include Dr. Jalari Ramu; Dr. Krupavaram. B; Dr. K. Vinod Kumar; Badri. Sirisha; Ramireddy Harshith Reddy; Dr. Kasetti Ashok Babu; Dr. Manju Navaneetham; Dr. Kannan Kilavan Packiam; Dr. Sattenapalli Lakshmi Savithri; and Vinjavarapu Lakshmi. Anusha.
The application for the patent was published on June 12, 2026, under issue no. 24/2026.
Abstract: ABSTRACT: Title: Nanoparticle-Based Controlled Drug Delivery System for Enhanced Brain Targeting in Neurodegenerative Disorders The present invention relates to a nanoparticle-based controlled drug delivery system designed to enhance targeted delivery of therapeutic agents to the brain for the treatment of neurodegenerative disorders. The system comprises biocompatible and biodegradable polymeric nanoparticles encapsulating at least one active pharmaceutical ingredient, wherein the nanoparticles are engineered to facilitate transport across the blood–brain barrier. The nanoscale size and surface functionalization enable improved brain localization and cellular uptake. The formulation provides controlled and sustained drug release governed by polymer degradation and diffusion kinetics, thereby maintaining therapeutic drug concentrations over extended durations. The delivery platform enhances bioavailability, protects the drug from premature degradation, and minimizes systemic toxicity through site-specific targeting. The invention is applicable for the treatment and management of neurological conditions including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and other central nervous system disorders. The system is further adaptable for various therapeutic agents and is compatible with scalable pharmaceutical manufacturing processes, offering a clinically viable solution for advanced brain-targeted drug delivery.
Disclaimer: Curated by HT Syndication.
